Table 2.
Summary of some of the best described interactions involving VAP-B
| Region involved | Protein partner | Disease associated | References |
|---|---|---|---|
| N.D.a | CERT | Chlamydia infections | (63, 64) |
| MSP domain | NS5A | Hepatitis C | (56) |
| MSP domain | NS5B | Hepatitis C | (57) |
| N.D. | NS3/4A (NS4A) | Hepatitis C | (59) |
| MSP domain | Eph receptors (EphA2, EphA4, EphA5, EphA6, EphA7, EphA8) | Hepatitis C | (51, 56, 57) |
| MSP domain | ATF6 | Hepatitis C, ALS8 | (76) |
| MSP domain | NS1/2 | Diarrheab | (55) |
| N.D. | OSBP1 | Common coldc | (60) |
| N.D. | PTPIP51 | AD, PD, FTD, ALSd | (46) |
| MSP domain | α-Synuclein | PDd | (47, 71) |
| MSP domain | p97–FAF1 complex | ALS8 | (88) |
| MSP domain | ASNA1–TRC complex | ALS8 | (88) |
AD, Alzheimer's disease; ALS, amyotrophic lateral sclerosis; FTD, frontotemporal dementia; MSP, major sperm protein; PD, Parkinson's disease.
a
Not determined.
b
Caused by norovirus infection.
c
Caused by rhinovirus infection.
d
These pathologies are associated with tethering disruption.